Combining One MR-Guided HDR Brachytherapy and One SABR Treatment for Favorable Risk Prostate Cancer in a Phase 23 Study

What this Trial Is About

Prostate cancer patients with favorable-risk disease are commonly treated with lengthy courses of image guided radiation therapy IGRT. Researchers are investigating a shorter, more convenient approach by combining one stereotactic ablative body radiotherapy SABR treatment with one high-dose rate HDR brachytherapy treatment guided by MRI. This study aims to assess if this combined approach can maintain good cancer control while reducing side effects, treatment time, and costs. Participants will first undergo imaging and marker placement to prepare for treatment. Then they receive one SABR treatment delivering a high dose to the prostate and seminal vesicles. About one week later, imaging is repeated to plan a single HDR brachytherapy dose targeted to the prostate and visible tumor areas. Both treatments use imaging guidance to accurately deliver radiation. Dosimetric data will be collected during treatment. Patients will be monitored closely from the start of SABR treatment through five years. Assessments include evaluations of urinary, rectal, and sexual function, side effects at multiple time points, blood tests for PSA and testosterone, and quality of life questionnaires. Samples of urine, blood, and biopsy tissue will be collected before and after treatment for further study. This thorough follow-up aims to track safety, side effects, quality of life, and cancer control over time.

2 Ablative RadioTherapy Treatments for Prostate Cancer